Search Results

You are looking at 31 - 40 of 132 items for :

  • "molecular targets" x
  • All content x
Clear All
Full access

John A. Thompson

understanding of risk and prognostic factors, discovery of aberrant signaling pathways driving melanoma, and FDA approval of targeted immunotargeted and molecularly targeted therapies. This article details these areas of progress. Table 1 New Melanoma

Full access

John A. Thompson

investigated further. Molecularly Targeted Agents A better understanding of the genetic landscape of advanced melanoma has led to the successful targeting of key mutations, especially BRAF mutations, which appear to be most frequent in younger

Full access

Shumei Kato, Vivek Subbiah, and Razelle Kurzrock

actionable molecular targets have emerged. There are currently >70 targeted agents FDA approved for the treatment of solid and hematologic malignancies, and the numbers continue to increase ( http

Full access

Renuka Iyer and Kaunteya Reddy

. Therapy PNET Therapy Before 2011 Before the discovery of molecular targeted agents, the mainstay of treatment for NETs was initial debulking surgery for early-stage disease and a wide spectrum of options, from observation to locoregional therapy or a

Full access

Frederick D. Tsai and Robert I. Haddad

12-month increase in median overall survival in this cohort. 5 These results have provided a new avenue of treatment for SDC. Elsewhere in this issue, Lin et al demonstrate the utility of next-generation sequencing (NGS) in deriving molecular

Full access

Al B. Benson III

behind that in breast and other cancers for which researchers now have an array of different molecular targets as templates for drug development. Importantly, international clinical trials in colorectal cancer provided a mechanism to create extensive

Full access

tissue samples and correlate this with response to combination temsirolimus and neratinib in HER2-amplified tumors Assess abnormalities in PI3K-PTEN-AKT-mTOR pathway through analysis of expression of PTEN and upstream molecular targets IGF1-R, EGFR, and

Full access

Margaret von Mehren

Verweij J Von Oosterom A Blay J . Imatinib Mesylate is an active agent for GIST but does not yield responses in other soft tissue sarcomas that are unselected for a molecular target . Eur J Cancer 2003 ; 39 : 2006 – 2011 . 60 Chugh R Thomas

Full access

Wallace Akerley

drug yet targeted to that mutation. 1 Molecular targets with emergent treatment pathways include HER2, MET amplification, BRAF V600E , and RET . Dr. Akerley stated, “Multiplex panels to identify all actionable mutations are critical to the care

Full access

Marcy Neuburg

therapy regimens . J Am Acad Dermatol 1999 ; 40 : 177 – 186 . 25. Mita MM Mita A Rowinsky EK . The molecular target of rapamycin (mTOR) as a therapeutic target against cancer . Cancer Biol Ther 2003 ; 2 ( suppl 1 ): S169 – 177 . 26